| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 1,600 | 5,080 | 7,990 | 6,690 | 9,380 |
| Sales Growth | -68.50% | -36.42% | +19.43% | -28.68% | -21.24% |
| Net Income | -10,010 | -16,560 | -6,560 | -2,750 | -3,110 |
| Net Income Growth | +39.55% | -152.44% | -138.55% | +11.58% | -178.14% |
Lpath Inc Cmn A (LPTN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lpath, Inc., headquartered in San Diego, California, is the category leader in lipid-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. It is a biotechnology company whose lead product candidate, ASONEP is a monoclonal antibody against a validated cancer target, sphingosine-1-phosphate (S1P) that is currently in phase I clinical trials for cancer. A second product candidate, iSONEP (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical models of age-related macular degeneration (AMD) and retinopathy and is in a Phase 1 clinical trial in wet-AMD patients. Lpath's third product candidate, Lpathomab, is an antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been long recognized as a valid disease target (cancer, neuropathic pain, fibrosis). The company is based in San Diego, California.